Viatris Inc. (VTRS)
Viatris is a global healthcare company that focuses on providing affordable, off-patent medicines to millions of patients around the world.
Is Viatris Inc. a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: Provides essential, high-demand medicines. Worth weighing: Currently reporting a net loss. Below, we lay out what it does, what its numbers mean, and the honest risks, so you can decide for yourself.
Over about 2 years to 2026-07-31. This is the share price only - reinvesting the dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has Viatris Inc. actually fallen?
Over the last 2 years of daily prices, Viatris Inc. fell as much as −46% from a high to a later low. Drops of this size are a normal part of owning a share - worth knowing in advance, so a dip doesn't come as a shock.
Worst peak-to-trough fall in the daily closing price over the period we hold. Past falls are not a forecast - it can fall further, or recover.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Transformation into a high-growth, innovative pharmaceutical leader.
Persistent losses and inability to compete with newer medical technologies.
What does Viatris Inc. do?
Viatris was formed by merging Upjohn and Mylan, creating a giant that specialises in 'generic' drugs—the cheaper, non-branded versions of medicines that have lost their patent protection. The cash rolls in from selling these high-volume, essential treatments to pharmacies and hospitals globally. Keep an eye on how they manage their debt and whether they can pivot toward newer, more complex medicines to replace the revenue from older products.
On our factor screen it looks strongest on momentum and value, and weakest on quality.
- ✓Pays a dividend - about 2.7% a year
- ✓Growing - revenue up about 8% over the year
- Value screens high (82/100)
- Momentum screens high (90/100)
- Provides essential, high-demand medicines
- Attractive dividend yield for income-focused observers
- Low valuation relative to expected earnings
- Quality screens low (25/100)
- Intense price competition from other generic manufacturers
- Regulatory changes affecting drug pricing
- Potential for legal costs related to pharmaceutical products
What do Viatris Inc.'s numbers mean?
How much money does Viatris Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Viatris Inc. pay a dividend?
Yes - Viatris Inc. currently pays a dividend of about 2.7% a year (the yearly payout as a share of the price). A dividend is a slice of profit handed to shareholders; the yield moves as the price moves, and a company can cut or stop it.
What do the numbers say about Viatris Inc.'s dividend?
There's no rating here, and we don't judge whether the dividend will continue - that would be advice. Here are the figures income investors usually look at, and what each one means, so you can weigh it up yourself.
Figures are from the latest available data and can be distorted by one-off results. Past payments don't predict future ones, and a dividend can be cut at any time. This lays out the numbers to help you understand them - it is not a view on what will happen.
When does Viatris Inc. report earnings, and how did recent quarters go?
Viatris Inc. is next scheduled to report on about 2026-08-06 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-05-07 | $0.50 | $0.59 | Beat +18% |
| 2026-02-26 | $0.53 | $0.57 | Beat +7% |
| 2025-11-06 | $0.62 | $0.67 | Beat +9% |
| 2025-08-07 | $0.56 | $0.62 | Beat +12% |
| 2025-05-08 | $0.49 | $0.50 | Beat +2% |
| 2025-02-27 | $0.57 | $0.54 | Missed -6% |
Across the last 6 quarters here, Viatris Inc. came in ahead of what analysts expected 5 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Viatris Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Viatris Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Provides essential, high-demand medicines
- Attractive dividend yield: The yearly dividend as a percentage of the share price - roughly the income you'd earn from dividends alone. for income-focused observers
- Low valuation relative to expected earnings
- Currently reporting a net loss
- Heavy reliance on older, off-patent drugs
- Significant debt load from the company's formation
- Intense price competition from other generic manufacturers
- Regulatory changes affecting drug pricing
- Potential for legal costs related to pharmaceutical products
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained return to consistent profitability
- A major, successful acquisition of a high-growth biotech firm
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.